GSK plc
Search results
Vaccines Help Protect Us. Every year, vaccination saves up to 5 million lives around the world. But an additional 1.5 million lives could be saved with improved vaccination coverage. 1. Why vaccines matter. Our Vaccines at a Glance. 500 million +. people vaccinated annually with our vaccines worldwide. 1.3 million.
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK.
17 Apr 2023 · The Sanofi vaccine, known as VidPrevtyn Beta, is protein-based and instead contains copies of the SARS-CoV-2 spike protein from the beta variant. This variant was first detected in South Africa and was classified as a variant of concern in December 2020.
24 Jun 2005 · Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation. The vaccine candidate showed a favorable safety and tolerability profile.
17 Mei 2005 · PARIS and LONDON – May 17, 2021 – The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers.
Sanofi has been a leader in vaccines for over 100 years. The combination of our innovative vaccines and global reach means that many diseases do not hold the power they once did. Our determination to improve public health motivates us to de-velop new vaccines to address still unmet medical needs. Fueled
17 Mei 2021 · Sanofi, the French pharmaceutical company, said on Monday that it would move the experimental Covid-19 vaccine it is developing with GlaxoSmithKline into a late-stage trial after the shot...
